摘要
目的:观察不同剂量巴曲酶联合依达拉奉治疗进展性脑梗死的疗效。方法:将90例进展性脑梗死患者随机分为:常规剂量巴曲酶组(对照组)、常规剂量(隔日使用)巴曲酶加依达拉奉组(常联组)和非常规剂量(连续使用)巴曲酶加依达拉奉组(非联组)。治疗前、治疗后7 d、14 d进行神经功能缺损程度评分,并于治疗前、治疗后3 d、7 d检测纤维蛋白原(FIB)。结果:常联组14 d总有效率、显效率分别为的90%、67%,非联组14 d总有效率、显效率分别为97%、77%,明显高于对照组的90%、27%,差异有显著性(P<0.01)。非联组总有效率、显效率高于常联组,但差异无显著性意义(P>0.05)。结论:巴曲酶联合依达拉奉治疗进展性脑梗死有较好的临床疗效和安全性。
Objective： To observe therapeutic effect of different doses of batroxobin combined with edaravone on the patients with progressive cerebral infarction. Methods： 90 patients with progressive cerebral infarction were randomly divided into normal dose batroxobin group （control group）, normal dose batroxobin combined with edaravone group （normal combined group） and uncommon dose batroxo- bin combined with edaravone group（ uncommon combined group）. Neurological deficit scores （NDS） were evaluated before treatment, and 7 days and 14 days after treatment. Fibrinogen（FIB） was determined before treatment and 3 days and 7 days after treatment. Results： Effective rate and notable effective rate of normal combined group after 14 days of treatment were 90% and 67%, and 97%, 77% of uncommon combined group, which were both obviously higher than those of control group 90% and 27%. Effective rate and notable effective rate of uncommon combined group were higher than those of normal combined group, but the difference was not significantly. Conclusion： The treatment of batroxobin combined with edaravone on progressive cerebral infarction is effective and safe.
出处
《药学与临床研究》
2009年第3期246-248,共3页
Pharmaceutical and Clinical Research
关键词
巴曲酶
依达拉奉
进展性脑梗死
Batroxobin
Edaravone
Progressive cerebral infarction
